Companies /Healthcare

Takeda Pharmaceutical Co Ltd ADR

NYSE: TAK Drug Manufacturers - Specialty & Generic
$20.91
▲ $0.90 (+4.50%) today
Markets closed · 2:02pm ET

24/7 Wall St. View

Price Prediction $25.83 +23.5% Our analysts’ 12-month view: target, optimistic case, and floor. TAK price prediction →

TAK at a Glance

Valuation
Market cap
$66.8B
P/E ratio
298.7
Profitability
Revenue (TTM)
$4.62T
Profit margin
-3.5%
EPS (TTM)
$0.07
Price
52-week range
$13 – $21
24/7 target
$25.83
Street target
$23.08

Headquartered in Nihonbashi-honcho 2-chome, Chuo Fiscal year ends March NYSE: TAK takeda.com

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income. It reports a single operating segment.

Its revenue is organized into six key business areas:
- **Gastroenterology:** ENTYVIO, GATTEX/REVESTIVE, TAKECAB/VOCINTI, EOHILIA.
- **Rare Diseases:** TAKHZYRO, ELAPRASE, ADVATE, LIVTENCITY, VONVENDI, ADZYNMA.
- **Plasma-Derived Therapies:** immunoglobulins such as HYQVIA, CUVITRU and GAMMAGARD LIQUID, plus albumin.
- **Oncology:** ADCETRIS, LEUPLIN/ENANTONE, NINLARO, ICLUSIG, FRUZAQLA, MIMRYLO.
- **Vaccines:** QDENGA, NUVAXOVID.
- **Neuroscience:** VYVANSE/ELVANSE, TRINTELLIX, ORZEYFUL.

R&D focuses on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience (orexin biology), and Oncology. Key late-stage assets include zasocitinib, arcotatug tavatecan, elritercept, TAK-928 and fazirsiran.

The United States is the largest market, followed by Europe, Japan, Latin America and China. The company is executing a transformation program and is led by CEO Julie Kim. Updated

Latest Activity

Biggest movers · On the open
Gainers
  • REGNRegeneron$914.2+11.7%
  • AZNAstraZeneca$186.72+7.1%
  • TAKTakeda Pharmaceutical$21.21+6.0%
  • GILDGilead Sciences$174.95+5.6%
  • MDLZMondelez International$65.63+5.0%
Losers
  • INTCIntel$65.27-29.1%
  • APPSDigital Turbine$9.26-12.4%
  • MSTRStrategy$125.22-11.6%
  • DOCNDigitalOcean$89.25-10.7%
  • DDOGDatadog$238.8-10.2%

Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.

Read more
TAKTakeda Pharmaceutical
New 52-week high$20.43+0.3% vs prior high · 2026-10-22

Takeda's ADRs just set a fresh 52-week high at $20.43, the fourth record in a week for the drugmaker.

Read more
TAKTakeda Pharmaceutical
New 52-week high$19.45+2.1% vs prior high · 2026-09-17

Takeda Pharmaceutical touched $19.45, a fresh 52-week high that clears the September 17 peak by 2.1%. The ADR and the OTC line are both at the top of their range.

Read more

TAK Coverage

Frequently Asked Questions

What does Takeda Pharmaceutical do?

Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company. It researches, develops, manufactures and commercializes pharmaceutical products and also earns out-licensing and service income.

What is the TAK stock price target?

24/7 Wall St.'s 12-month price target for TAK is $25.83, rated Buy. The Wall Street consensus target is $23.08. TAK price prediction →